Recruiting
Phase 1
Phase 2

Observational Study

Sponsor:

Orion Corporation, Orion Pharma

Code:

NCT07563738

Conditions

Mesothelioma

Pancreatic Cancer

NSCLC (Advanced Non-small Cell Lung Cancer)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ODM-212

Ipilimumab and nivolumab

Gemcitabine and nab-paclitaxel

sotorasib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-07. This information was provided to ClinicalTrials.gov by Orion Corporation, Orion Pharma on 2026-05-04.